Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NervGen Pharma ( (TSE:NGEN) ) has issued an announcement.
NervGen Pharma Corp. updated on its at-the-market equity program, reporting the sale of 385,200 common shares, generating net proceeds of $1,111,777. Additionally, the company granted 200,000 stock options to a director, reflecting its ongoing strategic financial activities to support its clinical and preclinical programs.
The most recent analyst rating on (TSE:NGEN) stock is a Buy with a C$4.00 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the TSE:NGEN Stock Forecast page.
Spark’s Take on TSE:NGEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:NGEN is a Neutral.
NervGen Pharma presents a high-risk, high-reward profile typical of early-stage biotech firms. Financial performance is weak due to ongoing R&D costs with no revenue, but technical indicators show positive momentum. Corporate events highlight potential upside from clinical advancements. However, the lack of earnings and reliance on financing remain significant concerns.
To see Spark’s full report on TSE:NGEN stock, click here.
More about NervGen Pharma
NervGen Pharma Corp. is a clinical-stage biotech company focused on developing innovative treatments for nervous system repair in neurotrauma and neurologic diseases. Their lead candidate, NVG-291, is being tested in clinical trials for spinal cord injury, and they are also evaluating NVG-300 for ischemic stroke and spinal cord injury.
YTD Price Performance: 6.93%
Average Trading Volume: 175,320
Technical Sentiment Signal: Buy
Current Market Cap: C$258.5M
For detailed information about NGEN stock, go to TipRanks’ Stock Analysis page.